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of 14. On the ﬁrst admission at our service, she presented
orbital and lower limbs edema, systemic arterial hyperten-
sion, sclerodactyly and proximal skin sclerosis. No muscle
weakness and vasculitis were observed. Laboratory ﬁndingsvailable online xxx
ntroduction
uvenile systemic sclerosis (JSSc) is an autoimmune disease,
haracterized by disordered collagen accumulation, leading
o disseminated vascular lesions in skin and internal organs
brosis, including the kidneys.1–3
Worthy of note, renal involvement is a rare manifestation
nd occurs in 1–12% of JSSc patients, mainly with arterial
ypertension and/or proteinuria.1,3–5 Scleroderma renal crisis
as also rarely reported5,6 and to our knowledge, nephrotic
yndrome (NS) was described in only one JSSc patient with
embranous nephropathy.7
We  report herein a patient who presented NS as the ﬁrst
anifestation of JSSc with focal segmental glomerulosclerosis
FSGS).Please cite this article in press as: Couto SB, et al. Nephrotic syndrome a
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icenses/by-nc-nd/4.0/).Case  report
A female patient presented vomiting, malaise and general-
ized edema at the age of 12 years. She had systemic arterial
hypertension, hypoalbuminemia (<2.5 mg/dL) and proteinuria
(urine protein/creatinine ratio ≥2.0 mg/g). She was diagnosed
with NS and treated with prednisone (60 mg/m2/day) with pro-
gressive reduction. During follow-up she had several relapses
of NS, one of them associated to the upper respiratory tract
infections and another one with spontaneous bacterial peri-
tonitis, and was referred to our University Hospital at the ages the ﬁrst manifestation of juvenile systemic scleroderma. Rev Bras
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Fig. 1 – Nailfold capillaroscopy showing moderate capillary
dilation (arrow A) and mild focal devascularization (arrow
idiopathic NS.12,13B) in patient with juvenile systemic sclerosis.
revealed serum albumin 0.9 g/dL (normal levels 3.8–5.6), total
cholesterol 637 mg/dL (normal <199), low density lipoprotein
(LDL) 439 mg/dL (normal <110), serum urea 18 mg/dL (nor-
mal  15–45), serum creatinine 0.53 mg/dL (normal 0.6–0.9),
25-hydroxyvitamin D 5 ng/mL (normal 30–100 ng/mL) and
proteinuria 7.8 g/day. Hands X-ray revealed no bone abnor-
malities. Antinuclear antibodies (ANA), rheumatoid factor,
and anti-Scl-70 (anti-topoisomerase I), anti-Sm, Anti-SS-A/Ro,
Anti-SS-B/La and anti-smooth muscle (anti-SMA) antibodies
were negative. C3 and C4 fractions of the complement sys-
tem were normal. Serology for hepatitis A, B and C, human
immunodeﬁciency virus (HIV), cytomegalovirus, Epstein–Barr
virus and syphilis were negative. Echocardiogram was normal.
Moderate capillary dilation and mild focal devascularization
were observed in nailfold capillaroscopy, compatible with
early stage of scleroderma (scleroderma pattern) (Fig. 1).
Percutaneous renal biopsy guided by ultrasound revealed
focal segmental glomerulosclerosis and direct immunoﬂuo-Please cite this article in press as: Couto SB, et al. Nephrotic syndrome a
Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2014.08.004
rescence were negative (Fig. 2A and B). Therefore, she fullﬁlled
the provisional classiﬁcation criteria for JSSc.6 The patient
was treated with oral 25-hydroxyvitamin D (800 IU/day),
Fig. 2 – Optical microscopy in renal biopsy of patient with juveni
Masson trichrome staining showing occasional wrinkling and th
double contour appearance in rare loops, segmental mesangial p
atrophy and interstitial. (B) Histological ﬁndings in the Silver sta
glomerular basement membrane (arrow) ﬁbrosis in less than 10% 1 6;x  x x(x x):xxx–xxx
methotrexate (0.5 mg/kg/week) and amlodipin (0.15 mg/kg).
Prednisone (60 mg/m2/day) was administered for 4 consec-
utive weeks, followed by alternate-day (40 mg/m2) for 2
consecutive months, with tapering for 4 months and then
stopping this medication. Currently, she is being treated with
methotrexate 15 mg/week, without edema and proteinuria.
Discussion
To our knowledge, this was the ﬁrst case reported with steroid-
sensitive NS and FSGS as the ﬁrst manifestation of JSSc.
The most important systemic manifestation of JSSc are
cutaneous lesions, specially induration proximal to metacar-
pophalangeal joints, sclerodactly and edema,1,3,4 as observed
in the present case. The capillaroscopy can be used to eval-
uate changes of microcirculation in the capillaries of the
nail bed.8 These ﬁndings strongly suggest systemic sclerosis
diagnosis,8 as evidenced herein, and not found in cutaneous
scleroderma.9
Kidney involvement was rarely described in pediatric scle-
roderma population. The most frequent renal manifestations
were arterial hypertension and proteinuria. Renal crisis in
JSSc patients ranges from 0.7% to 4%.1,3–5 This is a life-
threatening complication with abrupt onset of malignant
arterial hypertension, proteinuria and/or hematuria, throm-
botic microangiopathy and potentially can result to end stage
kidney disease.6,10,11
Adult scleroderma NS has a great spectrum varying from
minimal changes disease and secondary amyloidosis to
rapidly progressive renal failure and proliferative changes
lesions with crescents, and membranous nephropathy. NS
was only reported in one 12-year-old female patient who  pre-
sented with scleroderma ﬁve years after the onset of this renal
involvement with membranous nephropathy.7
Importantly, our patient had steroid sensitive NS with a
severe histological pattern of FSGS. This glomerulopathy is an
important cause of proteinuria and chronic renal disease in
children and adolescents, accounting in 5–15% of all cases ofs the ﬁrst manifestation of juvenile systemic scleroderma. Rev Bras
The treatment of JSCc is performed according to organs
and systems involvement. Methotrexate has been shown to
improve skin scores in early diffuse SSc.14 Additionally, renal
le systemic sclerosis. (A) Histological ﬁndings in the
ickening of glomerular basement membrane, causing
roliferation, mesangial matrix expansion, with tubular
ining showing occasional double contour appearance of
 of glomeruli and normal vessels.
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reatment of FSGS includes glucocorticoid and antihyperten-
ive drugs, as used in our patient.12 Interestingly, the absence
f proteinuria with complete remission after treatment sug-
ests adequate renal long-term outcome.13
In conclusion, we  reported a rare case of NS with FSGS as
he ﬁrst manifestation of scleroderma. Therefore, renal biopsy
s mandatory in JSSc patients with sustained proteinuria or NS.
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